A recent clinical trial reveals that Wegovy, a popular weight-loss drug containing semaglutide, shows promising results in treating liver diseases like MASH. The study, published in the New England Journal of Medicine, involved over 800 participants across 37 countries. Wegovy significantly reduced liver inflammation and scarring, offering hope for millions affected by fatty liver diseases.